首页|Metformin protects against cardiac and renal damage in diabetic cardiac arrest patients
Metformin protects against cardiac and renal damage in diabetic cardiac arrest patients
扫码查看
点击上方二维码区域，可以放大扫码查看
原文链接
NSTL
Elsevier
? 2022 Elsevier B.V.Introduction: Metformin is a first-line diabetic therapy that improves survival in a wide number of ischemic pathologies. We tested the association of metformin with markers of cardiac and renal injury in diabetic post-arrest patients. Methods: We performed a retrospective analysis of clinical outcomes in diabetic cardiac arrest patients with and without metformin therapy at a single academic medical center. We used generalized linear models to test the independent association of metformin, insulin, and other hypoglycemic agents with peak 24-hour serum creatinine and peak 24-hour serum troponin. Results: Metformin prescription at the time of SCA was independently associated with lower 24-hour peak serum troponin and lower 24-hour peak serum creatinine when compared to non-metformin patients. Conclusion: Metformin pretreatment may offer cardiac and renal protection for diabetic patients during sudden cardiac arrest.
Rutledge C.A.、Kaufman B.A.、Dezfulian C.、Elmer J.
展开 >
Division of Cardiology Vascular Medicine Institute Department of Medicine University of Pittsburgh
Department of Pediatrics Baylor College of Medicine
Departments of Emergency Medicine Critical Care Medicine and Neurology University of Pittsburgh
NSTL
Elsevier
